• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»dopaminergic progenitor cells

Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?

By Pallavi Madhiraju on May 13, 2026   Pharma & Biotech  

Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?

Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.

Recent Posts

  • Why Vetter’s Saarlouis expansion matters for sterile injectable supply chains
  • How AstraZeneca’s Owkin deal could push agentic AI deeper into drug development
  • EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?
  • Can Oryzon Genomics, S.A. turn iadademstat into a platform therapy for acute myeloid leukemia?
  • Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
  • How PharmAla Biotech Holdings Inc. is positioning APA-01 around traumatic brain injury and neurorehabilitation
  • What Can-Fite BioPharma Ltd.’s Phase 2b pancreatic cancer strategy reveals about immunotherapy combination economics
  • Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
  • FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity
  • Can BridgeBio’s Attruby narrow Pfizer’s Vyndamax lead in the ATTR-CM market?
  • Why Bristol Myers Squibb’s $15.2bn Hengrui alliance signals a pipeline reset
  • Why GSK’s SBP Group alliance could reshape chronic hepatitis B access in Chin
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes